Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
AstraZeneca
Daiichi Sankyo
Boehringer Ingelheim
Chubb
Accenture
Cantor Fitzgerald
Chinese Patent Office

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,303,146

« Back to Dashboard

Which drugs does patent 6,303,146 protect, and when does it expire?

Patent 6,303,146 protects GLUCOVANCE and is included in one NDA.

Protection for GLUCOVANCE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in twenty-six countries.
Summary for Patent: 6,303,146
Title: Solid oral dosage form comprising a combination of metformin and glibenclamide
Abstract:The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.
Inventor(s): Bonhomme; Yves (Charbonnieres les Bains, FR), Nicholson; Geoffrey (Aylesbury, GB), Cave; Gillian (Ellesmere Port, GB), Nicholson; Sarah J. (Helsby, GB)
Assignee: LIPHA (Lyons, FR)
Application Number:09/353,141
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Process; Formulation; Use;

Drugs Protected by US Patent 6,303,146

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-001 Jul 31, 2000 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-002 Jul 31, 2000 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-003 Jul 31, 2000 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,303,146

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98401781Jul 15, 1998

Non-Orange Book US Patents Family Members for Patent 6,303,146

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE38629 Solid oral dosage form comprising a combination of metformin and glibenclamide ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,303,146

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Uruguay 25611 ➤ Try a Free Trial
Taiwan I245632 ➤ Try a Free Trial
Taiwan 200303208 ➤ Try a Free Trial
Taiwan 555560 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Federal Trade Commission
UBS
Argus Health
Johnson and Johnson
Express Scripts
US Army
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.